Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study
Colomban, Tod, Leary, Ray-Coquard, Lortholary, Hardy-Bessard, Pfisterer, Du Bois, Kurzeder, Burges, Péron, Freyer, You B
Clin Cancer Res. 2019 Sep 1
Two prognostic populations of ovarian cancer patients defined by CA-125 modeled kinetic parameter KELIM™ (AGO-OVAR 7 & 9; ICON 7 AGO/GINECO/ MRC CTU/GCIG trials)
Benoit You, Olivier Colomban, Gilles Freyer, Alexandra Leary, Isabelle Laure Ray-Coquard, Alain Lortholary, Anne Claire Hardy Bessard, Jacobus Pfisterer, Andreas Du Bois, Christian Kurzeder, Alexander Burges, and Michel Tod
Journal of Clinical Oncology 2017 35:15_suppl, 5554-5554
A critical review of the analytical approaches for circulating tumor biomarker kinetics during treatment
You B, Almufti R, Wilbaux M, Oza A, Henin E, Freyer G, Tod M, Colomban O
Annals of Oncology 25: 41–56, 2014
Early prediction of treatment resistance in low-risk gestational trophoblastic neoplasia using population kinetic modelling of hCG measurements
You B, Harvey R, Henin E, Mitchell H, Golfier F, Savage PM, Tod M, Wilbaux M, Freyer G, Seckl MJ.
Br J Cancer. 2013 May 14;108(9):1810-6.
Predictive values of hCG clearance for risk of methotrexate resistance in low-risk gestational trophoblastic neoplasias
You B, Pollet-Villard M, Fronton L, Labrousse C, Schott AM, Hajri T, Girard P, Freyer G, Tod M, Tranchand B, Colomban O, Ribba B, Raudrant D, Massardier J, Chabaud S, Golfier F.
Ann Oncol. 2010 Aug;21(8):1643-50.
Prognostic value of modeled PSA clearance on biochemical relapse free survival after radical prostatectomy
You B, Girard P, Paparel P, Freyer G, Ruffion A, Charrié A, Hénin E, Tod M, Perrin P.
Prostate. 2009 Sep 1;69(12):1325-33.